Published in Cancer Weekly, July 9th, 2002
The work was done by scientists at the University of Texas (UT) M.D. Anderson Cancer Center in Houston and The University of Texas Southwestern Medical Center at Dallas.
Dr. Michael Rosenblum, professor of medicine at M.D. Anderson, said tests of VEGF121/rGelonin (VEGF/rGel) in mice demonstrated it could selectively destroy blood vessels supplying human solid tumors without harming the vasculature of normal tissue.
"This is like a 'Trojan...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.